Abstract
Pharmacokinetic variability in pediatric patients due to maturational changes in organ function, effects of concomitant disease, and drug toxicity or interactions commonly results in drug clearances that differ by a factor of 4 or 5. This intersubject pharmacokinetic variability has been shown to correlate to an increased likelihood of toxicity in patients with low drug clearances, and therapeutic failure in patients with high drug clearances [1, 2]. Pharmacokinetic and pharmacodynamic modeling strategies have been developed and incorporated into clinical studies intended to define the unique pharmacokinetics of anticancer drugs in pediatric patients, identify clinical correlates (e. g., patient characteristics, laboratory indices of organ function) of pharmacokinetic differences, and adjust dosage regimens to control for pharmacokinetic variability.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
W. E. Evans, W. R. Crom, M. Abromowitch, et al. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med. 314:471–477 (1986).
J. H. Rodman, M. Abromowitch, J. A. Sinkule et al. Clinical Pharmacodynamics of Continuous Infusion Teniposide: Systemic Exposure as a Determinant of Response in a Phase I trial. J. Clin. Oncol. 7:1007–1014 (1987).
J. H. Rodman, M. Sunderland, R. L. Kavanagh, J. Ochs, J. Yalowich, W. E. Evans, and G. K. Rivera. Pharmacokinetics of continuous infusion methotrexate and teniposide in pediatric cancer patients. Cancer Res. 50:4267–4271 (1990).
R. S. Day. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res. 46:3876–3885 (1986).
A. J. Coldman, C. M. L. Coppin, and J. H. Goldie. Models for Dose Intensity. Math. Biosci. 92:97–113 (1988).
C. C. Peck and J. H. Rodman. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimen. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Applied Therapeutics, Inc., Spokane, 1986, pp. 55–82.
D. Z. D’Argenio and A. Schumitzky. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp. Prog. Biomed. 9:115–134 (1979).
S. L. Beal. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab. Rev. 15:173–194 (1984).
S. L. Beal and L. B. Sheiner. NONMEM User’s Guides, NONMEM Project, University of California, San Francisco, 1989.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rodman, J.H., Evans, W.E. (1991). Targeted Systemic Exposure for Pediatric Cancer Therapy. In: D’Argenio, D.Z. (eds) Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9021-4_16
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9021-4_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9023-8
Online ISBN: 978-1-4757-9021-4
eBook Packages: Springer Book Archive